Will Japan Pharma Fall In Line With R&D Externalization Trends?
Executive Summary
Japanese pharma companies are generally following the same trends as their global counterparts when it comes to the externalization of R&D, and revenues from internal projects are set to fall over the next few years, with Takeda in particular expected to look much more to external opportunities.
You may also be interested in...
Refocus, Optimize, Externalize: Takeda Overhauls Global R&D
As it reported solid underlying growth in the fiscal first quarter, Takeda has unveiled a detailed implementation program for its stated strategic intent to refocus global R&D effort on selected R&D areas, in a major overhaul that will make much wider use of external partners and affect "significant" numbers of people across the company.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Genmab buys into ADCs; Roivant set to take on AbbVie in uveitis; Ipsen signs firs ADC pact; South Korea looks to build biotech momentum; and the end of the road for Acorda.